{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:43Z","timestamp":1787614843003,"version":"build-2736575974"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Acute leukemia (AL), which includes acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), is a hematological malignancy characterized by the uncontrolled proliferation of immature myeloid or lymphoid cells. Allogeneic stem cell transplantation (ASCT) remains a therapeutic option for patients with AL. Determination of transplantation indications is a key step in successful ASCT and in curing patients. Currently, the measurable residual disease (MRD) is used as a biomarker for response evaluation, relapse prediction, preemptive therapy, and post-remission treatment selection. In this review, we discuss the advantages and disadvantages of these techniques for MRD detection. We focused mainly on the residual disease-directed selection of transplant indications for patients with either AML or ALL and provided expert opinions in these settings. We also discuss the challenges associated with transplantation indications and propose expert opinions and future directions for the selection of indications for transplantation.<\/jats:p>","DOI":"10.1097\/bs9.0000000000000229","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T01:17:07Z","timestamp":1743211027000},"page":"e00229","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know"],"prefix":"10.1097","volume":"7","author":[{"given":"Xiao-Su","family":"Zhao","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Tong","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jun","family":"Chang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, No. 11 South Street of Xizhimen, Xicheng District, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"R1-20250325","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia.","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"R2-20250325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia.","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250325","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1016\/S2352-3026(22)00293-9","article-title":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.","volume":"9","author":"Chang","year":"2022","journal-title":"Lancet Haematol"},{"key":"R4-20250325","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"R5-20250325","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel.","volume":"143","author":"Gokbuget","year":"2024","journal-title":"Blood"},{"key":"R6-20250325","first-page":"596","article-title":"Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation.","volume":"110","author":"Algeri","year":"2025","journal-title":"Haematologica"},{"key":"R7-20250325","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.3324\/haematol.2024.285002","article-title":"Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.","volume":"109","author":"Atsuta","year":"2024","journal-title":"Haematologica"},{"key":"R8-20250325","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3324\/haematol.2023.284228","article-title":"A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China.","volume":"109","author":"Gong","year":"2024","journal-title":"Haematologica"},{"key":"R9-20250325","doi-asserted-by":"crossref","first-page":"101762","DOI":"10.1016\/j.xcrm.2024.101762","article-title":"A simplified and robust risk stratification model for stem cell transplantation in pediatric acute myeloid leukemia.","volume":"5","author":"Yang","year":"2024","journal-title":"Cell Rep Med"},{"key":"R10-20250325","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3324\/haematol.2023.283120","article-title":"Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?","volume":"108","author":"Swaminathan","year":"2023","journal-title":"Haematologica"},{"key":"R11-20250325","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3324\/haematol.2022.282639","article-title":"Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.","volume":"108","author":"Tettero","year":"2023","journal-title":"Haematologica"},{"key":"R12-20250325","doi-asserted-by":"crossref","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"R13-20250325","doi-asserted-by":"crossref","first-page":"217104","DOI":"10.1016\/j.canlet.2024.217104","article-title":"Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.","volume":"598","author":"Yan","year":"2024","journal-title":"Cancer Lett"},{"key":"R14-20250325","article-title":"Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia.","author":"Wang","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"R15-20250325","doi-asserted-by":"crossref","first-page":"e7074","DOI":"10.1002\/cam4.7074","article-title":"Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.","volume":"13","author":"Jia","year":"2024","journal-title":"Cancer Med"},{"key":"R16-20250325","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"R17-20250325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French Association Group.","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"key":"R18-20250325","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"R19-20250325","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"key":"R20-20250325","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.","volume":"125","author":"Dhedin","year":"2015","journal-title":"Blood"},{"key":"R21-20250325","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","article-title":"Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.","volume":"31","author":"Eckert","year":"2013","journal-title":"J Clin Oncol"},{"key":"R22-20250325","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s12185-022-03441-6","article-title":"Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.","volume":"116","author":"Han","year":"2022","journal-title":"Int J Hematol"},{"key":"R23-20250325","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations.","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"key":"R24-20250325","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1182\/bloodadvances.2024013182","article-title":"Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.","volume":"8","author":"Venditti","year":"2024","journal-title":"Blood Adv"},{"key":"R25-20250325","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2020007311","article-title":"Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.","volume":"137","author":"Ribera","year":"2021","journal-title":"Blood"},{"key":"R26-20250325","doi-asserted-by":"crossref","first-page":"e2115991","DOI":"10.1001\/jamanetworkopen.2021.15991","article-title":"Association between measurable residual disease in patients with intermediate-risk acute myeloid leukemia and first remission, treatment, and outcomes.","volume":"4","author":"Yu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R27-20250325","first-page":"55","article-title":"Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.","volume":"110","author":"Lazzarotto","year":"2025","journal-title":"Haematologica"},{"key":"R28-20250325","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: a GRAAPH-2014 Study.","volume":"42","author":"Kim","year":"2024","journal-title":"J Clin Oncol"},{"key":"R29-20250325","doi-asserted-by":"crossref","first-page":"451","DOI":"10.21147\/j.issn.1000-9604.2023.05.04","article-title":"MRD-directed and risk-adapted individualized stratified treatment of AML.","volume":"35","author":"Zhao","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"R30-20250325","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(23)00365-4","article-title":"Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?","volume":"11","author":"Chevallier","year":"2024","journal-title":"Lancet Haematol"},{"key":"R31-20250325","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/17474086.2023.2285985","article-title":"Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.","volume":"16","author":"Li","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"R32-20250325","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study.","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"R33-20250325","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajh.25417","article-title":"Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts.","volume":"94","author":"Zhao","year":"2019","journal-title":"Am J Hematol"},{"key":"R34-20250325","doi-asserted-by":"crossref","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci Adv"},{"key":"R35-20250325","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41556-021-00814-7","article-title":"Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis.","volume":"24","author":"Zhang","year":"2022","journal-title":"Nat Cell Biol"},{"key":"R36-20250325","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-023-00941-4","article-title":"Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study.","volume":"13","author":"Xu","year":"2023","journal-title":"Blood Cancer J"},{"key":"R37-20250325","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.16745","article-title":"The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.","volume":"192","author":"Duan","year":"2021","journal-title":"Br J Haematol"},{"key":"R38-20250325","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.2024024074","article-title":"Transplant in AML: just follow the NPM1 guide!","volume":"143","author":"Recher","year":"2024","journal-title":"Blood"},{"key":"R39-20250325","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1200\/JCO.23.01841","article-title":"Mitoxantrone versus liposomal daunorubicin in induction of pediatric AML with risk stratification based on flow cytometry measurement of residual disease.","volume":"42","author":"Tierens","year":"2024","journal-title":"J Clin Oncol"},{"key":"R40-20250325","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jtct.2022.06.005","article-title":"Hematopoietic cell transplantation in the treatment of pediatric acute myelogenous leukemia and myelodysplastic syndromes: guidelines from the American Society of Transplantation and Cellular Therapy.","volume":"28","author":"Tarlock","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R41-20250325","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1158\/1078-0432.CCR-18-1637","article-title":"Myeloablative haploidentical transplantation is superior to chemotherapy for patients with intermediate-risk acute myelogenous leukemia in first complete remission.","volume":"25","author":"Lv","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R42-20250325","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s11427-020-1754-6","article-title":"Th2 polarization in target organs is involved in the alleviation of pathological damage mediated by transplanting granulocyte colony-stimulating factor-primed donor T cells.","volume":"64","author":"Zhou","year":"2021","journal-title":"Sci China Life Sci"},{"key":"R43-20250325","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts.","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"key":"R44-20250325","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"R45-20250325","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R46-20250325","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","article-title":"Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R47-20250325","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00277-023-05160-2","article-title":"Pediatric chemotherapy versus allo-HSCT for adolescent and adult Philadelphia chromosome-negative ALL in first complete remission: a meta-analysis.","volume":"102","author":"Pan","year":"2023","journal-title":"Ann Hematol"},{"key":"R48-20250325","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"R49-20250325","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL.","volume":"42","author":"Foa","year":"2024","journal-title":"J Clin Oncol"},{"key":"R50-20250325","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma.","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"R51-20250325","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","article-title":"Combination targeted therapy in relapsed diffuse large B-cell lymphoma.","volume":"390","author":"Melani","year":"2024","journal-title":"N Engl J Med"},{"key":"R52-20250325","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R53-20250325","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41408-024-01127-2","article-title":"Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease.","volume":"14","author":"Lu","year":"2024","journal-title":"Blood Cancer J"},{"key":"R54-20250325","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"R55-20250325","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial.","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"R56-20250325","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R57-20250325","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjh.17460","article-title":"The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.","volume":"193","author":"Dholaria","year":"2021","journal-title":"Br J Haematol"},{"key":"R59-20250325","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1080\/10428194.2019.1576868","article-title":"Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.","volume":"60","author":"Deng","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R60-20250325","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"R61-20250325","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s11427-024-2666-8","article-title":"Single-cell immune landscape of measurable residual disease in acute myeloid leukemia.","volume":"67","author":"Mo","year":"2024","journal-title":"Sci China Life Sci"}],"container-title":["Blood Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T01:18:19Z","timestamp":1743211099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BS9.0000000000000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bs9.0000000000000229","relation":{},"ISSN":["2543-6368"],"issn-type":[{"value":"2543-6368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}